Patent ID: 7700280

Claim:
A method of assessing whether an ovarian cancer patient's tumor is resistant to cisplatin comprising the steps of: (a) measuring a gene expression level of at least one gene selected from the group consisting of S100A10 and S100A11 in (i) an ovarian cancer tumor sample taken from the patient, and (ii) a cisplatin responsive ovarian tumor sample; (b) comparing the expression level of said at least one gene in the ovarian cancer tumor sample taken from the patient and the cisplatin responsive ovarian tumor sample; and (c) determining that the ovarian cancer patient's tumor is resistant to cisplatin when the expression level of said at least one gene in the ovarian cancer tumor sample taken from the patient is at least 1.2-fold greater than the expression level of said at least one gene in the cisplatin responsive ovarian tumor sample.